fullPIERS Model study

  • Research type

    Research Study

  • Full title

    THE fullPIERS RISK PREDICTION MODEL FOR WOMEN WITH PRE-ECLAMPSIA: EXTERNAL VALIDATION, RECALIBRATION AND ADDED VALUE OF A NOVEL BIOMARKER (PLACENTAL GROWTH FACTOR)

  • IRAS ID

    180337

  • Contact name

    U. Vivian Ukah

  • Contact email

    Vivian.Ukah@cw.bc.ca

  • Sponsor organisation

    University of Oxford

  • Duration of Study in the UK

    0 years, 6 months, 0 days

  • Research summary

    The hypertensive disorders of pregnancy (HDP), with pre-eclampsia being the most dangerous, complicate about 10 % of pregnancy and are major contributors to maternal and perinatal morbidity and mortality. This is due to the severe complications that can result from them such as stroke, kidney failure and eclampsia for the mother, and fetal growth restriction and stillbirth for the baby.
    The ability to predict these adverse outcomes will aid the appropriate management and treatment by the early identification of women with higher risks of complications arising from HDP and applying timely interventions. Therefore, the fullPIERS model was developed to predict the risks of developing complications for women with pre-eclampsia in high-resourced settings, so as to aid clinicians in managing such pregnancies. In order for the fullPIERS model to be introduced into clinical practice, it is necessary to assess its predictive ability in a similar population cohort other than the one in which it was developed in (external validation) and to improve the model where possible by adding new biomarkers as well as recalibrating the model if and when required for better predictive performance.
    Successfully validating the fullPIERS model externally and implementing it into routine clinical care will inform and guide clinical decisions, thereby aiding appropriate allocation of care and resources to the patients and contributing in reducing maternal morbidity and mortality resulting from pre-eclampsia.

  • REC name

    South Central - Oxford A Research Ethics Committee

  • REC reference

    16/SC/0291

  • Date of REC Opinion

    31 Aug 2016

  • REC opinion

    Further Information Favourable Opinion